Thompson AJ , Price KL , Lummis SC .

081925\Z\07\Z Wellcome Trust

	Figure 1. Residues that were mutated in this studyA, sequence alignment of human 5-HT3A and 5-HT3B subunits with Torpedo californica nACh receptor α and γ subunits, human GABAA receptor α1 subunit, and Lymnaea stagnalis AChBP. Residues mutated in this study are shown in bold on a grey background. The positions of the six binding loops A–F are indicated by black lines. B, a homology model of the 5-HT3A receptor showing the location of the A subunit residues (stick representation) mutated in this study. Note that the numbering of the A and B residues in panel A corresponds to the human 5-HT3 receptor, but the number in panel B is according to the mouse numbering used in this paper. Accession numbers for the alignment are: 5-HT3A P46098, 5-HT3B O95264, nACh α P02710, nACh γ P02714, GABA α1 P02710, AChBP P58154.
	Figure 2. 5-HT concentration–response and PTX concentration–inhibition curves for A and AB receptorsA, 5-HT concentration–response curves. Wild-type receptors were unaltered by MTSEA (comparisons are also shown in Fig. 4). The calculated EC50 values and Hill slopes can be found in Table 1. Typical EC50 5-HT responses are shown next to each curve. B, PTX concentration–inhibition curves. The presence of the B subunit is confirmed by a rightward shift in the PTX concentration–inhibition curve in heteromeric receptors. The mutants shown are examples, and are the same as those in Fig. 5.
	Figure 3. Relative EC50 values of wild-type and mutant receptorsAsterisks denote statistically different from wild-type. NF: non-functional at 100 μm 5-HT, or with an EC50 too high to be accurately determined. Relative values are shown as the differences ± SED. Data from Table 1. The dotted line represents the difference between wild-type 5-HT3A and wild-type 5-HT3AB responses.
	Figure 4. The effect of MTSEA on wild-type and mutant receptorsThe EC50 or Imax obtained after MTSEA treatment is compared to that obtained before treatment. BLOCK: complete inhibition by MTSEA. Asterisks denote statistically different from wild-type. NF: non-functional at 100 μm 5-HT. Relative values are expressed as the difference ± SED. Data from Table 1.
	Figure 5. Agonist (5-HT) and antagonist (d-TC) protection of mutant receptors from MTS modificationA, AR92C and AR92CB receptors are completely protected from MTSEA–biotin modification by the presence of either agonist (5-HT) or antagonist (d-TC). There is no effect of MTSEA–biotin on ABQ92C receptors. R92 is a loop D residue located on the A subunit complementary (−) face; Q92 is the equivalent B subunit residue. B, AT181C and AT181CB receptors are completely protected from MTSEA modification by the presence of either agonist (5-HT) or antagonist (d-TC). There is no effect of MTSEA on ABK181C receptors. T181 is a loop B residue located on the A subunit principal (+) face; K181 is the equivalent B subunit residue. Typical current traces from oocytes expressing AR92C (C) or ABQ92C (D) receptors are also shown. 5-HT application (200 μm for AR92C or 30 μm for ABQ92C) is denoted by a black bar above the trace. Arrows indicate applications of MTSEA–biotin (2 mm with or without 1 mm 5-HT) for 2 min, followed by wash for 2 min (see methods for details). E, structures of MTSEA and MTSEA–biotin.
	Figure 6. The effects of DTT on homomeric and heteromeric receptors containing A subunit double cysteine mutations (AS206C/E229C) in the C and F loopsA, 5-HT-induced currents are only seen after application of DTT (10 mm for 1 min). A subsequent application of MTSEA (2 mm for 1 min) inhibits this response; this inhibition can be reversed by DTT. B, DTT treatment is also required for 5-HT-induced responses in heteromeric AS206C/E229CB receptors. C, the locations of S206 and E229 on a 5-HT3 receptor homology model (template PDB ID; 2PGZ). D, Concentration–response curves for homomeric and heteromeric receptors containing the A subunit double cysteine mutant. Parameters derived from these curves (Table 2) are consistent with those expected for homomeric and heteromeric responses. E, Disulphide bonds spontaneously reform in AS206C/E229CB mutant receptors. Following removal of DTT, peak current responses to 5-HT (100 μm) decline with an exponential time course (τ = 0.17 ± 0.01 min−1), but recover following several 10 s DTT applications (arrows). All traces are representative of ≥4 separate experiments.

Barrera, Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors. 2005, Pubmed

Barrera, Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors. 2005, Pubmed
Beene, Tyrosine residues that control binding and gating in the 5-hydroxytryptamine3 receptor revealed by unnatural amino acid mutagenesis. 2004, Pubmed , Xenbase
Bhattacharya, Uropathic observations in mice expressing a constitutively active point mutation in the 5-HT3A receptor subunit. 2004, Pubmed , Xenbase
Boileau, Mapping the agonist binding site of the GABAA receptor: evidence for a beta-strand. 1999, Pubmed , Xenbase
Boyd, Assembly and cell surface expression of homomeric and heteromeric 5-HT3 receptors: the role of oligomerization and chaperone proteins. 2002, Pubmed , Xenbase
Brady, Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. 2001, Pubmed
Brams, Crystal structures of a cysteine-modified mutant in loop D of acetylcholine-binding protein. 2011, Pubmed
Chen, Determination of external loop topology in the serotonin transporter by site-directed chemical labeling. 1998, Pubmed
Collingridge, A nomenclature for ligand-gated ion channels. 2009, Pubmed
Das, The 5-HT3B subunit confers reduced sensitivity to picrotoxin when co-expressed with the 5-HT3A receptor. 2003, Pubmed
Das, Molecular determinants of picrotoxin inhibition of 5-hydroxytryptamine type 3 receptors. 2005, Pubmed
Davies, The 5-HT3B subunit is a major determinant of serotonin-receptor function. 1999, Pubmed , Xenbase
Dubin, The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. 1999, Pubmed , Xenbase
Exley, Chaperone protein 14-3-3 and protein kinase A increase the relative abundance of low agonist sensitivity human alpha 4 beta 2 nicotinic acetylcholine receptors in Xenopus oocytes. 2006, Pubmed , Xenbase
Gleitsman, An intersubunit hydrogen bond in the nicotinic acetylcholine receptor that contributes to channel gating. 2008, Pubmed
Goldin, Maintenance of Xenopus laevis and oocyte injection. 1992, Pubmed , Xenbase
Hansen, Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. 2005, Pubmed
Hapfelmeier, Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 receptor. 2003, Pubmed
Hilf, X-ray structure of a prokaryotic pentameric ligand-gated ion channel. 2008, Pubmed
Holbrook, Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. 2009, Pubmed
Hu, The 5-HT3B subunit confers spontaneous channel opening and altered ligand properties of the 5-HT3 receptor. 2008, Pubmed
Kelley, A cytoplasmic region determines single-channel conductance in 5-HT3 receptors. 2003, Pubmed
Lochner, Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor. 2010, Pubmed , Xenbase
Mukhtasimova, Detection and trapping of intermediate states priming nicotinic receptor channel opening. 2009, Pubmed
Nelson, Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors. 2003, Pubmed , Xenbase
Price, A hydrogen bond in loop A is critical for the binding and function of the 5-HT3 receptor. 2008, Pubmed
Price, The role of tyrosine residues in the extracellular domain of the 5-hydroxytryptamine3 receptor. 2004, Pubmed , Xenbase
Rayes, Number and locations of agonist binding sites required to activate homomeric Cys-loop receptors. 2009, Pubmed
Reeves, The molecular basis of the structure and function of the 5-HT3 receptor: a model ligand-gated ion channel (review). 2002, Pubmed
Reeves, Prediction of 5-HT3 receptor agonist-binding residues using homology modeling. 2003, Pubmed
Sedelnikova, Mapping the rho1 GABA(C) receptor agonist binding pocket. Constructing a complete model. 2005, Pubmed
Spier, The role of tryptophan residues in the 5-Hydroxytryptamine(3) receptor ligand binding domain. 2000, Pubmed
Sullivan, Defining the roles of Asn-128, Glu-129 and Phe-130 in loop A of the 5-HT3 receptor. 2006, Pubmed
Sullivan, Mapping the agonist binding site of the nicotinic acetylcholine receptor. Orientation requirements for activation by covalent agonist. 2000, Pubmed , Xenbase
Thompson, Loop B is a major structural component of the 5-HT3 receptor. 2008, Pubmed
Thompson, Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. 2011, Pubmed , Xenbase
Thompson, Ginkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that overlaps the picrotoxin binding site. 2011, Pubmed , Xenbase
Thompson, Locating an antagonist in the 5-HT3 receptor binding site using modeling and radioligand binding. 2005, Pubmed
Thompson, The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT3 receptors. 2007, Pubmed , Xenbase
Thompson, The 5-HT3 receptor as a therapeutic target. 2007, Pubmed
Thompson, The structural basis of function in Cys-loop receptors. 2010, Pubmed
Thompson, 5-HT3 receptors. 2006, Pubmed
Tremblay, Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. 2003, Pubmed
Venkataraman, Identification of critical residues in loop E in the 5-HT3ASR binding site. 2002, Pubmed
Walstab, RIC-3 exclusively enhances the surface expression of human homomeric 5-hydroxytryptamine type 3A (5-HT3A) receptors despite direct interactions with 5-HT3A, -C, -D, and -E subunits. 2010, Pubmed
Ward, Protein engineering and the study of structure--function relationships in receptors. 1990, Pubmed
Wu, A conserved cysteine residue in the third transmembrane domain is essential for homomeric 5-HT3 receptor function. 2010, Pubmed
Yan, Structural features of the ligand-binding domain of the serotonin 5HT3 receptor. 1999, Pubmed
Yan, Mapping residues in the ligand-binding domain of the 5-HT(3) receptor onto d-tubocurarine structure. 2006, Pubmed
Zwart, Four pharmacologically distinct subtypes of alpha4beta2 nicotinic acetylcholine receptor expressed in Xenopus laevis oocytes. 1998, Pubmed , Xenbase